Concert Pharma (CNCE) Reports Complete Enrollment of 12mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

January 22, 2019 7:02 AM EST Send to a Friend
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login